Intrahepatic Cholangiocarcinoma

Surgical Clinics of North America

Volumn 90, Issue 4, 2010, Pages 817-837

  Poultsides, George A ^a   Zhu, Andrew X ^b,c   Choti, Michael A ^d   Pawlik, Timothy M ^d  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Biliary cancer; Hepatectomy; Liver cancer; Liver resection; Peripheral cholangiocarcinoma

Indexed keywords

CISPLATIN; EPIRUBICIN; FLOXURIDINE; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GEMCITABINE; MITOMYCIN;

ADVANCED CANCER; ANATOMICAL CONCEPTS; ARTIFICIAL EMBOLISM; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LAPAROSCOPY; LYMPHADENECTOMY; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MEDICAL SOCIETY; METASTASIS; MONOTHERAPY; MULTIDETECTOR COMPUTED TOMOGRAPHY; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; REVIEW; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT OUTCOME; TUMOR ABLATION; TUMOR VOLUME; UNITED STATES; BILE DUCT NEOPLASMS; CHEMOEMBOLIZATION; CHOLANGIOCARCINOMA; DIAGNOSTIC IMAGING; INCIDENCE; INTRAHEPATIC BILE DUCT; LIVER RESECTION; MULTIMODALITY CANCER THERAPY; PROCEDURES; SURVIVAL RATE;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHEMOEMBOLIZATION, THERAPEUTIC; CHOLANGIOCARCINOMA; COMBINED MODALITY THERAPY; DIAGNOSTIC IMAGING; HEPATECTOMY; HUMANS; INCIDENCE; NEOPLASM STAGING; SURVIVAL RATE; UNITED STATES;

EID: 77954641348     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2010.04.011     Document Type: Review

References (85)

1. Lazaridis K.N., Gores G.J. Cholangiocarcinoma. Gastroenterology 2005, 128(6):1655-1667.
2. Vauthey J.N., Blumgart L.H. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 1994, 14(2):109-114.
3. Carpizo D.R., D'Angelica M. Management and extent of resection for intrahepatic cholangiocarcinoma. Surg Oncol Clin N Am 2009, 18(2):289-305. viii-ix.
4. Aljiffry M., Abdulelah A., Walsh M., et al. Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. J Am Coll Surg 2009, 208(1):134-147.
5. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002, 2:10.
6. Shaib Y.H., Davila J.A., McGlynn K., et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?. J Hepatol 2004, 40(3):472-477.
7. Taylor-Robinson S.D., Foster G.R., Arora S., et al. Increase in primary liver cancer in the UK, 1979-94. Lancet 1997, 350(9085):1142-1143.
8. Kato I., Kuroishi T., Tominaga S. Descriptive epidemiology of subsites of cancers of the liver, biliary tract and pancreas in Japan. Jpn J Clin Oncol 1990, 20(3):232-237.
9. Welzel T.M., McGlynn K.A., Hsing A.W., et al. Impact of classification of hilar cholangiocarcinomas (Klatskin tumors) on the incidence of intra- and extrahepatic cholangiocarcinoma in the United States. J Natl Cancer Inst 2006, 98(12):873-875.
10. El-Serag H.B., Engels E.A., Landgren O., et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. Hepatology 2009, 49(1):116-123.
11. Shaib Y.H., El-Serag H.B., Davila J.A., et al. Risk factors of intrahepatic cholangiocarcinoma in the United States: a case-control study. Gastroenterology 2005, 128(3):620-626.
12. Donato F., Gelatti U., Tagger A., et al. Intrahepatic cholangiocarcinoma and hepatitis C and B virus infection, alcohol intake, and hepatolithiasis: a case-control study in Italy. Cancer Causes Control 2001, 12(10):959-964.
13. Kobayashi M., Ikeda K., Saitoh S., et al. Incidence of primary cholangiocellular carcinoma of the liver in Japanese patients with hepatitis C virus-related cirrhosis. Cancer 2000, 88(11):2471-2477.
14. Welzel T.M., Graubard B.I., El-Serag H.B., et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol 2007, 5(10):1221-1228.
15. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001, 33(6):1353-1357.
16. Nathan H., Pawlik T.M., Wolfgang C.L., et al. Trends in survival after surgery for cholangiocarcinoma: a 30-year population-based SEER database analysis. J Gastrointest Surg 2007, 11(11):1488-1496. [discussion: 1496-7].
17. Patel A.H., Harnois D.M., Klee G.G., et al. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol 2000, 95(1):204-207.
18. Tamandl D., Herberger B., Gruenberger B., et al. Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma. Ann Surg Oncol 2008, 15(10):2787-2794.
19. Yamasaki S. Intrahepatic cholangiocarcinoma: macroscopic type and stage classification. J Hepatobiliary Pancreat Surg 2003, 10(4):288-291.
20. Chung Y.E., Kim M.J., Park Y.N., et al. Varying appearances of cholangiocarcinoma: radiologic-pathologic correlation. Radiographics 2009, 29(3):683-700.
21. Manfredi R., Barbaro B., Masselli G., et al. Magnetic resonance imaging of cholangiocarcinoma. Semin Liver Dis 2004, 24(2):155-164.
22. Chen L.D., Xu H.X., Xie X.Y., et al. Enhancement patterns of intrahepatic cholangiocarcinoma: comparison between contrast-enhanced ultrasound and contrast-enhanced CT. Br J Radiol 2008, 81(971):881-889.
23. Miller G., Schwartz L.H., D'Angelica M. The use of imaging in the diagnosis and staging of hepatobiliary malignancies. Surg Oncol Clin N Am 2007, 16(2):343-368.
24. Maetani Y., Itoh K., Watanabe C., et al. MR imaging of intrahepatic cholangiocarcinoma with pathologic correlation. AJR Am J Roentgenol 2001, 176(6):1499-1507.
25. Anderson C.D., Rice M.H., Pinson C.W., et al. Fluorodeoxyglucose PET imaging in the evaluation of gallbladder carcinoma and cholangiocarcinoma. J Gastrointest Surg 2004, 8(1):90-97.
26. 18F-FDG PET in intrahepatic cholangiocarcinoma. Eur J Nucl Med Mol Imaging 2003, 30(11):1467-1472.
27. 18F-fluorodeoxyglucose positron emission tomography influences management decisions in patients with biliary cancer. J Am Coll Surg 2008, 206(1):57-65.
28. Petrowsky H., Wildbrett P., Husarik D.B., et al. Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma. J Hepatol 2006, 45(1):43-50.
29. Goere D., Wagholikar G.D., Pessaux P., et al. Utility of staging laparoscopy in subsets of biliary cancers: laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma. Surg Endosc 2006, 20(5):721-725.
30. Weber S.M., Jarnagin W.R., Klimstra D., et al. Intrahepatic cholangiocarcinoma: resectability, recurrence pattern, and outcomes. J Am Coll Surg 2001, 193(4):384-391.
31. Tan J.C., Coburn N.G., Baxter N.N., et al. Surgical management of intrahepatic cholangiocarcinoma-a population-based study. Ann Surg Oncol 2008, 15(2):600-608.
32. Sotiropoulos G.C., Bockhorn M., Sgourakis G., et al. R0 liver resections for primary malignant liver tumors in the noncirrhotic liver: a diagnosis-related analysis. Dig Dis Sci 2009, 54(4):887-894.
33. Endo I., Gonen M., Yopp A.C., et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg 2008, 248(1):84-96.
34. Konstadoulakis M.M., Roayaie S., Gomatos I.P., et al. Fifteen-year, single-center experience with the surgical management of intrahepatic cholangiocarcinoma: operative results and long-term outcome. Surgery 2008, 143(3):366-374.
35. Lang H., Sotiropoulos G.C., Sgourakis G., et al. Operations for intrahepatic cholangiocarcinoma: single-institution experience of 158 patients. J Am Coll Surg 2009, 208(2):218-228.
36. Nakagohri T., Kinoshita T., Konishi M., et al. Surgical outcome and prognostic factors in intrahepatic cholangiocarcinoma. World J Surg 2008, 32(12):2675-2680.
37. Shimada K., Sano T., Nara S., et al. Therapeutic value of lymph node dissection during hepatectomy in patients with intrahepatic cholangiocellular carcinoma with negative lymph node involvement. Surgery 2009, 145(4):411-416.
38. Nathan H., Cameron J.L., Choti M.A., et al. The volume-outcomes effect in hepato-pancreato-biliary surgery: hospital versus surgeon contributions and specificity of the relationship. J Am Coll Surg 2009, 208(4):528-538.
39. Nakagawa T., Kamiyama T., Kurauchi N., et al. Number of lymph node metastases is a significant prognostic factor in intrahepatic cholangiocarcinoma. World J Surg 2005, 29(6):728-733.
40. Nathan H., Aloia T.A., Vauthey J.N., et al. A proposed staging system for intrahepatic cholangiocarcinoma. Ann Surg Oncol 2009, 16(1):14-22.
41. Choi S.B., Kim K.S., Choi J.Y., et al. The prognosis and survival outcome of intrahepatic cholangiocarcinoma following surgical resection: association of lymph node metastasis and lymph node dissection with survival. Ann Surg Oncol 2009, 16(11):3048-3056.
42. Okabayashi T., Yamamoto J., Kosuge T., et al. A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer 2001, 92(9):2374-2383.
43. Greene F., Page D., Flemming I., et al. AJCC cancer staging manual 2002, Springer-Verlag, New York. 6th edition.
44. Ikeda K., Saitoh S., Koida I., et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993, 18(1):47-53.
45. Inoue K., Makuuchi M., Takayama T., et al. Long-term survival and prognostic factors in the surgical treatment of mass-forming type cholangiocarcinoma. Surgery 2000, 127(5):498-505.
46. Parkin D.M., Srivatanakul P., Khlat M., et al. Liver cancer in Thailand. I. A case-control study of cholangiocarcinoma. Int J Cancer 1991, 48(3):323-328.
47. Srivatanakul P., Parkin D.M., Jiang Y.Z., et al. The role of infection by Opisthorchis viverrini, hepatitis B virus, and aflatoxin exposure in the etiology of liver cancer in Thailand. A correlation study. Cancer 1991, 68(11):2411-2417.
48. Srivatanakul P., Parkin D.M., Khlat M., et al. Liver cancer in Thailand. II. A case-control study of hepatocellular carcinoma. Int J Cancer 1991, 48(3):329-332.
49. Ohtsuka M., Ito H., Kimura F., et al. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br J Surg 2002, 89(12):1525-1531.
50. Paik K.Y., Jung J.C., Heo J.S., et al. What prognostic factors are important for resected intrahepatic cholangiocarcinoma?. J Gastroenterol Hepatol 2008, 23(5):766-770.
51. Uenishi T., Kubo S., Yamazaki O., et al. Indications for surgical treatment of intrahepatic cholangiocarcinoma with lymph node metastases. J Hepatobiliary Pancreat Surg 2008, 15(4):417-422.
52. Shimada M., Yamashita Y., Aishima S., et al. Value of lymph node dissection during resection of intrahepatic cholangiocarcinoma. Br J Surg 2001, 88(11):1463-1466.
53. Edge S., Byrd D., Compton C., et al. AJCC cancer staging manual 2010, Springer-Verlag, New York. 7th edition.
54. Weimann A., Varnholt H., Schlitt H.J., et al. Retrospective analysis of prognostic factors after liver resection and transplantation for cholangiocellular carcinoma. Br J Surg 2000, 87(9):1182-1187.
55. Suzuki S., Sakaguchi T., Yokoi Y., et al. Clinicopathological prognostic factors and impact of surgical treatment of mass-forming intrahepatic cholangiocarcinoma. World J Surg 2002, 26(6):687-693.
56. Tamandl D., Kaczirek K., Gruenberger B., et al. Lymph node ratio after curative surgery for intrahepatic cholangiocarcinoma. Br J Surg 2009, 96(8):919-925.
57. Asakura H., Ohtsuka M., Ito H., et al. Long-term survival after extended surgical resection of intrahepatic cholangiocarcinoma with extensive lymph node metastasis. Hepatogastroenterology 2005, 52(63):722-724.
58. Murakami Y., Yokoyama T., Takesue Y., et al. Long-term survival of peripheral intrahepatic cholangiocarcinoma with metastasis to the para-aortic lymph nodes. Surgery 2000, 127(1):105-106.
59. DeOliveira M.L., Cunningham S.C., Cameron J.L., et al. Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg 2007, 245(5):755-762.
60. Jan Y.Y., Yeh C.N., Yeh T.S., et al. Clinicopathological factors predicting long-term overall survival after hepatectomy for peripheral cholangiocarcinoma. World J Surg 2005, 29(7):894-898.
61. Guglielmi A., Ruzzenente A., Campagnaro T., et al. Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection. World J Surg 2009, 33(6):1247-1254.
62. Bodingbauer M., Tamandl D., Schmid K., et al. Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases. Br J Surg 2007, 94(9):1133-1138.
63. Yamamoto M., Takasaki K., Otsubo T., et al. Recurrence after surgical resection of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg 2001, 8(2):154-157.
64. Chou F.F., Sheen-Chen S.M., Chen Y.S., et al. Surgical treatment of cholangiocarcinoma. Hepatogastroenterology 1997, 44(15):760-765.
65. Eckel F., Schmid R.M. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007, 96(6):896-902.
66. Huitzil-Melendez F.D., O'Reilly E.M., Duffy A., et al. Indications for neoadjuvant, adjuvant, and palliative chemotherapy in the treatment of biliary tract cancers. Surg Oncol Clin N Am 2009, 18(2):361-379. x.
67. Hezel A.F., Zhu A.X. Systemic therapy for biliary tract cancers. Oncologist 2008, 13(4):415-423.
68. Verderame F., Russo A., Di Leo R., et al. Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers. Ann Oncol 2006, 17(Suppl 7):vii, 68-vii, 72.
69. Valle J., Wasan H., Palmer D.H., et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010, 362(14):1273-1281.
70. Bengala C., Bertolini F., Malavasi N., et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 2010, 102(1):68-72.
71. Zhu A.X., Meyerhardt J.A., Blaszkowsky L.S., et al. Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol 2010, 11(1):48-54.
72. Malka D., Trarbach T., Fartoux L., et al. A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: interim analysis of the BINGO trial [abstract: 4520]. J Clin Oncol 2009, 27(Suppl):15s.
73. Philip P.A., Mahoney M.R., Allmer C., et al. Phase II study of erlotinib in patients with advanced biliary cancer. J Clin Oncol 2006, 24(19):3069-3074.
74. Ramanathan R.K., Belani C.P., Singh D.A., et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009, 64(4):777-783.
75. Shinohara E.T., Mitra N., Guo M., et al. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma. Int J Radiat Oncol Biol Phys 2008, 72(5):1495-1501.
76. Zeng Z.C., Tang Z.Y., Fan J., et al. Consideration of the role of radiotherapy for unresectable intrahepatic cholangiocarcinoma: a retrospective analysis of 75 patients. Cancer J 2006, 12(2):113-122.
77. Kemeny N.E., Niedzwiecki D., Hollis D.R., et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006, 24(9):1395-1403.
78. Cantore M., Mambrini A., Fiorentini G., et al. Phase II study of hepatic intraarterial epirubicin and cisplatin, with systemic 5-fluorouracil in patients with unresectable biliary tract tumors. Cancer 2005, 103(7):1402-1407.
79. Jarnagin W.R., Schwartz L.H., Gultekin D.H., et al. Regional chemotherapy for unresectable primary liver cancer: results of a phase II clinical trial and assessment of DCE-MRI as a biomarker of survival. Ann Oncol 2009, 20(9):1589-1595.
80. Shitara K., Ikami I., Munakata M., et al. Hepatic arterial infusion of mitomycin C with degradable starch microspheres for unresectable intrahepatic cholangiocarcinoma. Clin Oncol (R Coll Radiol) 2008, 20(3):241-246.
81. Tanaka N., Yamakado K., Nakatsuka A., et al. Arterial chemoinfusion therapy through an implanted port system for patients with unresectable intrahepatic cholangiocarcinoma-initial experience. Eur J Radiol 2002, 41(1):42-48.
82. Llovet J.M., Real M.I., Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002, 359(9319):1734-1739.
83. Lo C.M., Ngan H., Tso W.K., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35(5):1164-1171.
84. Gusani N.J., Balaa F.K., Steel J.L., et al. Treatment of unresectable cholangiocarcinoma with gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg 2008, 12(1):129-137.
85. Burger I., Hong K., Schulick R., et al. Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 2005, 16(3):353-361.